|Awarded On||June 18, 2010|
|Title||Company Recruitment, Relocation and Formation|
|Program||Product Development Research|
|Award Mechanism||Company Recruitment|
|Institution/Organization||Peloton Therapeutics, Inc.|
|Principal Investigator/Program Director||Tim Kutzkey|
|Cancer Sites||Lung and Bronchus, Multiple Sites|
Peloton Therapeutics aims to become a leading oncology company through the discovery and development of superior therapeutics, delivering extraordinary value to its employees, investors, and ultimately, cancer patients. The Company will initiate efforts with three cutting edge small molecule discovery programs, sourced from top investigators at The University of Texas Southwestern Medical Center (UTSWMC), including Dr. Steven McKnight, a world-recognized leader in the area of gene regulation.
Each of these programs represents a unique approach to cancer therapy, from blocking the tumor's critical need for adaptation to a limited oxygen supply to poisoning its ability to self-renew and proli...